2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

2:30PM-4:00PM: Abstract Number: 922

Negative Regulation of IL-17 Receptor Signaling By Regnase-1 Limits Immunopathology in a Mouse Model of Psoriatic Skin Disease

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

2:30PM-4:00PM: Abstract Number: 962

No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I: Psoriatic Arthritis – Treatment

2:30PM-4:00PM: Abstract Number: 916

Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies

B Cell Biology and Targets in Autoimmune Disease I

2:30PM-4:00PM: Abstract Number: 983

Objectively Assessed Sedentary Behaviour and Light Physical Activity Are Associated with Long-Term Cardiovascular Risk in People Living with Rheumatoid Arthritis Independently of Moderate-to-Vigorous Physical Activity

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 972

Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics I

2:30PM-4:00PM: Abstract Number: 935

Pretreatment Plasma IL-6 Levels Are Responsible for Bone Erosion Progression on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis

Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

2:30PM-4:00PM: Abstract Number: 938

Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study

Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

2:30PM-4:00PM: Abstract Number: 931

Rates of Lipid Testing and Statin Prescriptions Among SLE and Diabetes Mellitus Patients in a Nationwide Medicaid Cohort

Health Services Research I: Workforce and Quality of Care in Rheumatology

2:30PM-4:00PM: Abstract Number: 971

Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics I

2:30PM-4:00PM: Abstract Number: 936

Reliability and Responsiveness of an Omeract Tenosynovitis Magnetic Resonance Imaging Scoring System for the Rheumatoid Arthritis Wrist and Hand

Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

2:30PM-4:00PM: Abstract Number: 966

Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

2:30PM-4:00PM: Abstract Number: 929

Retinal Examinations Among SLE Patients Newly-Initiating Hydroxychloroquine in a U.S. Medicaid SLE Population, 2000-10

Health Services Research I: Workforce and Quality of Care in Rheumatology

2:30PM-4:00PM: Abstract Number: 923

Retinoic Acid Inhibits Expression of Interleukin 9 By Altering Enhancer Architecture

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

2:30PM-4:00PM: Abstract Number: 958

Safety and Efficacy of ABT-122, a TNF and IL-17–Targeted Dual Variable Domain (DVD)–Ig™, in Psoriatic Arthritis Patients with Inadequate Response to Methotrexate: Results from a Phase 2 Trial

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I: Psoriatic Arthritis – Treatment

2:30PM-4:00PM: Abstract Number: 969

Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].